These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31818449)

  • 1. One year follow-up of patients with reduced left ventricular ejection fraction (LVEF) on lipoprotein apheresis.
    Giurgea GA; Karkutli E; Granegger S; Berent R; Derfler K; Sinzinger H
    Atheroscler Suppl; 2019 Dec; 40():44-48. PubMed ID: 31818449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
    Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
    Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV; Afanasieva OI; Il'ina LN; Safarova MS; Adamova IY; Matchin YG; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic effects of regular lipoprotein-apheresis.
    Sinzinger H; Steiner S; Derfler K
    Atheroscler Suppl; 2017 Nov; 30():122-127. PubMed ID: 29096827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
    Safarova MS; Ezhov MV; Afanasieva OI; Matchin YG; Atanesyan RV; Adamova IY; Utkina EA; Konovalov GA; Pokrovsky SN
    Atheroscler Suppl; 2013 Jan; 14(1):93-9. PubMed ID: 23357149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis.
    Banyai S; Streicher J; Strobl W; Gabriel H; Gottsauner-Wolf M; Rohac M; Weidinger F; Hörl WH; Derfler K
    Metabolism; 1998 Sep; 47(9):1058-64. PubMed ID: 9751233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
    Tselmin S; Julius U; Weinert N; Bornstein SR; Schatz U
    Atheroscler Suppl; 2019 Dec; 40():38-43. PubMed ID: 31818448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
    Ezhov MV; Il'ina LN; Safarova MS; Afanasieva OI; Adamova IY; Atanesyan RV; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2013 Jan; 14(1):101-5. PubMed ID: 23357150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.
    Kroon AA; van't Hof MA; Demacker PN; Stalenhoef AF
    Atherosclerosis; 2000 Oct; 152(2):519-26. PubMed ID: 10998482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.
    de Lorgeril M; Salen P; Bontemps L; Belichard P; Geyssant A; Itti R
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):473-8. PubMed ID: 10069684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S; Fischer S; Weiss N; Julius U
    Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
    Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
    J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging.
    Bohl S; Kassner U; Eckardt R; Utz W; Mueller-Nordhorn J; Busjahn A; Thomas HP; Abdel-Aty H; Klingel R; Marcovina S; Dietz R; Steinhagen-Thiessen E; Schulz-Menger J; Vogt A
    Ther Apher Dial; 2009 Apr; 13(2):129-37. PubMed ID: 19379152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
    Geiss HC; Otto C; Hund-Wissner E; Parhofer KG
    Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
    Ma L; Waldmann E; Ooi EMM; Chan DC; Barrett HPR; Watts GF; Parhofer KG
    Eur J Clin Invest; 2019 Feb; 49(2):e13053. PubMed ID: 30447089
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.